COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.
作者信息
Nachar Victoria R, Perissinotti Anthony J, Marini Bernard L, Karimi Yasmin H, Phillips Tycel J
机构信息
University of Michigan Rogel Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
出版信息
Ann Hematol. 2023 Sep;102(9):2635-2637. doi: 10.1007/s00277-023-05315-1. Epub 2023 Jun 9.
Abstract
摘要
相似文献
1
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.接受靶向CD20的T细胞衔接双特异性抗体治疗B细胞非霍奇金淋巴瘤患者的COVID-19感染结局
Ann Hematol. 2023 Sep;102(9):2635-2637. doi: 10.1007/s00277-023-05315-1. Epub 2023 Jun 9.
2
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.CD20×CD3 双特异性抗体治疗淋巴瘤：2023 年美国临床肿瘤学会年会最新进展。
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
3
Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.用抗CD20×抗CD3双特异性双抗体有效抑制人B细胞淋巴瘤异种移植瘤
Cancer Lett. 2002 Mar 8;177(1):29-39. doi: 10.1016/s0304-3835(01)00758-3.
4
Glofitamab CD20-TCB bispecific antibody.戈利木单抗CD20-TCB双特异性抗体。
Leuk Lymphoma. 2021 Dec;62(13):3098-3108. doi: 10.1080/10428194.2021.1953016. Epub 2021 Jul 15.
5
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.异体造血干细胞移植后复发或难治性 B 细胞淋巴瘤的 FBTA05（Bi20）[一种三功能双特异性抗 CD3 x 抗 CD20 抗体]与供者淋巴细胞输注（DLI）联合免疫治疗：一项研究者发起的、开放标签、非随机、非对照、剂量递增的 I/II 期试验研究方案。
J Transl Med. 2013 Jul 2;11:160. doi: 10.1186/1479-5876-11-160.
6
Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.在临床前小鼠模型中通过靶向趋化因子受体CXCR5对B细胞非霍奇金淋巴瘤进行免疫治疗。
Int J Cancer. 2014 Dec 1;135(11):2623-32. doi: 10.1002/ijc.28893. Epub 2014 Apr 29.
7
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.抗 CD20/CD3 T 细胞依赖的双特异性抗体用于治疗 B 细胞恶性肿瘤。
Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.
8
Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.通过CD20-243双特异性抗体同时靶向CD20和HLA-DR来对抗非霍奇金淋巴瘤。
MAbs. 2014 May-Jun;6(3):740-8. doi: 10.4161/mabs.28613. Epub 2014 Mar 26.
9
An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.一种针对 CD52 和 CD20 的 IgG1 样双特异性抗体，用于治疗 B 细胞恶性肿瘤。
Methods. 2019 Feb 1;154:70-76. doi: 10.1016/j.ymeth.2018.08.008. Epub 2018 Aug 24.
10
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.使用CD3xCD19双特异性抗体和CD28共刺激对低度B细胞淋巴瘤进行局部区域治疗。II. 细胞免疫反应评估
Int J Cancer. 2001 Feb 15;91(4):516-22. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1069>3.0.co;2-a.
引用本文的文献
1
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对B细胞淋巴增殖性疾病患者双特异性抗体治疗的影响。
Blood Adv. 2025 Aug 26;9(16):4180-4189. doi: 10.1182/bloodadvances.2024015406.
2
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.Epcoritamab 治疗复发/难治性大 B 细胞淋巴瘤：关键性 EPCORE NHL-1 试验的 2 年随访结果。
Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25.
3
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.莫舒替尼单抗联合 CHOP 方案治疗未经治疗的弥漫性大 B 细胞淋巴瘤的安全性和疗效：来自一项 2 期研究的结果。
Blood Adv. 2023 Oct 24;7(20):6055-6065. doi: 10.1182/bloodadvances.2023010840.
本文引用的文献
1
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.在复发或难治性滤泡淋巴瘤患者中，双特异性抗体 mosunetuzumab 的安全性和疗效：一项单臂、多中心、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5.
2
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.mRNA 疫苗接种后非霍奇金淋巴瘤和慢性淋巴细胞白血病患者对 SARS-CoV-2 及其关注变体的体液反应。
J Clin Oncol. 2022 Sep 10;40(26):3020-3031. doi: 10.1200/JCO.22.00088. Epub 2022 Apr 18.
3
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
4
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.双特异性抗体治疗及其在感染方面的应用和风险：弥合知识差距。
Blood Rev. 2021 Sep;49:100810. doi: 10.1016/j.blre.2021.100810. Epub 2021 Feb 27.
5
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
6
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
7
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.一种新型的、天然形式的双特异性抗体可触发T细胞对B细胞的杀伤，在小鼠肿瘤模型和食蟹猴中具有强大的活性。
Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943.
Zotero 插件